For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues-Grant Revenues | - | - | 0 | - |
| Total revenues | - | 0 | 0 | 130 |
| Research and development | 3,199 | 3,401 | 3,651 | 3,152 |
| General and administrative | 3,081 | 2,806 | 2,741 | 2,543 |
| Total operating expenses | 6,280 | 6,207 | 6,392 | 5,695 |
| Loss from operations | - | -6,207 | -6,392 | -5,565 |
| Interest expense | 189 | 191* | 6 | 9 |
| Change in fair value of convertible promissory notes | - | 0* | 0 | 0 |
| Change in fair value of warrants | -104 | -3,186 | -1,044 | 956 |
| Change in fair value of tranche liability | 1,030 | - | - | - |
| Loss on warrants expiration | - | -3* | 724 | - |
| Loss on extinguishment of financial commitment assets and contingent warrants, net | -1,616 | - | - | - |
| Other income, net | 60 | -103* | 35 | 68 |
| Total other (expense) income, net | -611 | 2,889 | 1,797 | -897 |
| Loss before income tax | -6,891 | -3,331* | - | - |
| Provision for income taxes | 7 | 5* | - | - |
| Net loss | -6,898 | -3,336 | -4,595 | -6,462 |
| Net loss attributable to noncontrolling interest | 0 | 0 | -10 | -14 |
| Net loss attributable to serina | -6,898 | -3,336 | -4,585 | -6,448 |
| Basic EPS | -0.58 | -0.313 | -0.45 | -0.66 |
| Diluted EPS | -0.58 | -0.313 | -0.45 | -0.66 |
| Basic Average Shares | 12,047,000 | 10,661,000 | 10,339,000 | 10,004,000 |
| Diluted Average Shares | 12,047,000 | 10,661,000 | 10,339,000 | 10,004,000 |
Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc. (SER)